Treating Brain Injury

October, 2024

STTR NIH/NIA grant award to Neuronasal to conduct Phase 1 clinical dose finding research.

September,  2024

US Patent 12,090,130. Issued.  Method of Treating Brain Disorders

April,  2024

US Patent.  11,963,939 issued.  Use of N-acetylcysteine to Treat Central Nervous System Disorders

May, 2023

US Patent 11,660,278  issued. Use of N-acetylcysteine to Treat Central Nervous System Disorders.

November, 2022

Neuronasal received from the USPTO  notice of allowance on its core patent application US 16/700,588 Use of N-acetylcysteine to treat CNS Diseases. 

May, 2022

Review and validation of the MRS of human pilot study by world leading MRS group at John Hopkins Medical School

January, 2022
Neuronasal and its board of directors approved the Phase 1 clinical trial design and proceeding with plans for trial at a leading US medical school.  Amendment to approved IND planned for site and protocol. 
October,2021
Formulation development successful for preservative and increased concentration N-acetylcysteine drug product.  Exclusivity agreement with device manufacturer.

January, 2021. 

Successful completion of human pilot trial demonstrating nose to brain delivery of N-acetylcysteine to increase Glutathione  in three distinct brain regions using magnetic resonance spectroscopy.  This study forms the basis to proceed to full Phase 1 clinical trials. Success triggers further investment by ATAI Life to support trial preparation, formulation development and device testing.

September 23, 2020
Press Release ATAI collaboration: 

FDA approves Neuronasal IND.
Today, ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, and Neuronasal announced the completion of a pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers. Additionally, Neuronasal has been granted Investigational New Drug (IND) clearance by the FDA to continue phase I clinical trial development with ATAI’s support. Continue to read

June,  2020
Neuronasal received regulatory approval to start human pilot trial demonstrating nose to brain drug delivery.

December, 2019
ATAI Life Sciences announced an investment in Neuronasal Inc. To support the development of a treatment for concussion. Matthias Luz, MD and Greg Bates, PhD both of ATAI Life joined the Neuronasal board of directors as part of this investment.
 A copy of the press release from both companies is available at
 https://www.fiercebiotech.com/biotech/atai-backs-neuronasal-s-through-nose-concussion-treatment

June 3-6, 2019
Neuronasal has been selected as a finalist for Startup Stadium and will present at BIO in Philadelphia

May 8, 2019
Neuronasal has been selected to present at BioNJ at the Palace in Somerset, New Jersey

January 7-10,2019
Neuronasal is participating J.P. Morgan 37th Annual healthcare Conference

June 4, 2018  
Neuronasal is participating in RESI and BIO in Boston.

May 3, 2018
Neuronasal jointly filed broad US patent with Weill Cornell Medical School claiming FLAP inhibitors to treat brain injury and the delivery of FLAP inhibitors, including NAC, intranasally to treat brain injury including concussion.


April, 2017
Rajiv Ratan,MD PhD,  chairman of Neuronasal Science Advisory Board and Director of the Burke Research Institute Weill Cornell Medical School co authored Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis  in Stroke.